25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ARMP (Armata Pharmaceuticals Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Armata Pharmaceuticals Inc together

I guess you are interested in Armata Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Armata Pharmaceuticals Inc’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Armata Pharmaceuticals Inc’s Price Targets

I'm going to help you getting a better view of Armata Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Armata Pharmaceuticals Inc

I send you an email if I find something interesting about Armata Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Armata Pharmaceuticals Inc (30 sec.)










1.2. What can you expect buying and holding a share of Armata Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
5.0%

What is your share worth?

Current worth
$-0.81
Expected worth in 1 year
$-0.74
How sure are you?
32.5%

+ What do you gain per year?

Total Gains per Share
$0.07
Return On Investment
5.7%

For what price can you sell your share?

Current Price per Share
$1.28
Expected price per share
$1.1 - $2.22
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Armata Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)
$1.28
Intrinsic Value Per Share
$-9.05 - $0.93
Total Value Per Share
$-9.86 - $0.11

2.2. Growth of Armata Pharmaceuticals Inc (5 min.)




Is Armata Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$48m-$715.2k-$49.6m-98.6%

How much money is Armata Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$4.7m-$18m$13.3m281.6%
Net Profit Margin-647.5%-1,605.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Armata Pharmaceuticals Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#886 / 910

Most Revenue
#556 / 910

Most Profit
#349 / 910

Most Efficient
#678 / 910
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Armata Pharmaceuticals Inc?

Welcome investor! Armata Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Armata Pharmaceuticals Inc.

First you should know what it really means to hold a share of Armata Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Armata Pharmaceuticals Inc is $1.28. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Armata Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Armata Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.81. Based on the TTM, the Book Value Change Per Share is $0.02 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.47 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Armata Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.043.4%-0.16-12.6%-0.48-37.3%-0.24-18.9%-0.16-12.5%
Usd Book Value Change Per Share0.6046.6%0.021.4%-0.47-36.8%-0.06-4.8%-0.02-1.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.6046.6%0.021.4%-0.47-36.8%-0.06-4.8%-0.02-1.8%
Usd Price Per Share1.85-2.79-2.26-3.27-2.48-
Price to Earnings Ratio10.51-2.39--1.57--3.06--3.23-
Price-to-Total Gains Ratio3.10--0.84--6.58--3.02--13.24-
Price to Book Ratio-2.28--2.53--1.89-1.72-3.34-
Price-to-Total Gains Ratio3.10--0.84--6.58--3.02--13.24-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.28
Number of shares781
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.02-0.06
Usd Total Gains Per Share0.02-0.06
Gains per Quarter (781 shares)14.34-47.49
Gains per Year (781 shares)57.36-189.95
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1057470-190-200
201151040-380-390
301721610-570-580
402292180-760-770
502872750-950-960
603443320-1140-1150
704013890-1330-1340
804594460-1520-1530
905165030-1710-1720
1005745600-1899-1910

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%2.010.00.016.7%2.018.00.010.0%5.035.00.012.5%14.096.00.012.7%
Book Value Change Per Share2.02.00.050.0%3.09.00.025.0%6.014.00.030.0%13.026.01.032.5%35.071.04.031.8%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%2.00.038.05.0%3.00.0107.02.7%
Total Gains per Share2.02.00.050.0%3.09.00.025.0%6.014.00.030.0%13.026.01.032.5%35.071.04.031.8%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Armata Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.5960.018+3146%-0.471+179%-0.061+110%-0.023+104%
Book Value Per Share---0.813-1.144+41%-0.020-98%0.341-339%0.331-346%
Current Ratio--0.2340.263-11%1.027-77%2.522-91%2.726-91%
Debt To Asset Ratio--1.5561.492+4%1.001+55%0.774+101%0.603+158%
Debt To Equity Ratio----0%2.033-100%0.960-100%1.045-100%
Dividend Per Share----0%-0%-0%0.000-100%
Enterprise Value---15862948.500-4442355.500-72%-8269236.250-48%73405570.050-122%65864471.775-124%
Eps--0.044-0.161+466%-0.477+1184%-0.241+648%-0.160+463%
Ev To Ebitda Ratio---0.6341.265-150%0.141-551%-2.910+359%-1.161+83%
Ev To Sales Ratio--infnannan%-1.957nan%nannan%nannan%
Free Cash Flow Per Share---0.133-0.221+66%-0.384+189%-0.230+73%-0.154+16%
Free Cash Flow To Equity Per Share---0.1330.020-761%-0.011-92%0.021-724%0.006-2196%
Gross Profit Margin--1.0000.988+1%1.0040%0.998+0%0.972+3%
Intrinsic Value_10Y_max--0.926--------
Intrinsic Value_10Y_min---9.050--------
Intrinsic Value_1Y_max---0.513--------
Intrinsic Value_1Y_min---1.096--------
Intrinsic Value_3Y_max---1.080--------
Intrinsic Value_3Y_min---3.149--------
Intrinsic Value_5Y_max---1.091--------
Intrinsic Value_5Y_min---5.028--------
Market Cap46314368.000-136%109302051.500126619894.500-14%81864263.750+34%123615370.050-12%92291946.775+18%
Net Profit Margin----6.4750%-16.0500%-362.0030%-208.2080%
Operating Margin----6.0040%-15.9590%-390.8680%-213.4960%
Operating Ratio---2.897-100%10.115-100%389.242-100%218.411-100%
Pb Ratio-1.575+31%-2.276-2.527+11%-1.893-17%1.720-232%3.345-168%
Pe Ratio7.272-45%10.5102.386+340%-1.574+115%-3.058+129%-3.234+131%
Price Per Share1.280-45%1.8502.788-34%2.263-18%3.274-43%2.480-25%
Price To Free Cash Flow Ratio-2.408+31%-3.481-3.192-8%-1.614-54%-4.610+32%-5.167+48%
Price To Total Gains Ratio2.148-45%3.104-0.838+127%-6.579+312%-3.021+197%-13.238+526%
Quick Ratio--0.2080.239-13%0.858-76%2.332-91%2.545-92%
Return On Assets--0.030-0.038+225%-0.163+644%-0.106+454%-0.135+550%
Return On Equity----0%-0.2430%-0.1750%-0.2140%
Total Gains Per Share--0.5960.018+3146%-0.471+179%-0.061+110%-0.023+104%
Usd Book Value---48019000.000-50400750.000+5%-715250.000-99%10520100.000-556%11072625.000-534%
Usd Book Value Change Per Share--0.5960.018+3146%-0.471+179%-0.061+110%-0.023+104%
Usd Book Value Per Share---0.813-1.144+41%-0.020-98%0.341-339%0.331-346%
Usd Dividend Per Share----0%-0%-0%0.000-100%
Usd Enterprise Value---15862948.500-4442355.500-72%-8269236.250-48%73405570.050-122%65864471.775-124%
Usd Eps--0.044-0.161+466%-0.477+1184%-0.241+648%-0.160+463%
Usd Free Cash Flow---7850000.000-9857500.000+26%-13891750.000+77%-8683100.000+11%-5749525.000-27%
Usd Free Cash Flow Per Share---0.133-0.221+66%-0.384+189%-0.230+73%-0.154+16%
Usd Free Cash Flow To Equity Per Share---0.1330.020-761%-0.011-92%0.021-724%0.006-2196%
Usd Market Cap46314368.000-136%109302051.500126619894.500-14%81864263.750+34%123615370.050-12%92291946.775+18%
Usd Price Per Share1.280-45%1.8502.788-34%2.263-18%3.274-43%2.480-25%
Usd Profit--2600000.000-4729000.000+282%-18047250.000+794%-8666500.000+433%-5553725.000+314%
Usd Revenue---241500.000-100%1132250.000-100%614619.450-100%328984.725-100%
Usd Total Gains Per Share--0.5960.018+3146%-0.471+179%-0.061+110%-0.023+104%
 EOD+2 -6MRQTTM+19 -14YOY+19 -155Y+18 -1610Y+19 -17

3.3 Fundamental Score

Let's check the fundamental score of Armata Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-157.272
Price to Book Ratio (EOD)Between0-1-1.575
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.208
Current Ratio (MRQ)Greater than10.234
Debt to Asset Ratio (MRQ)Less than11.556
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.050.030
Total2/10 (20.0%)

3.4 Technical Score

Let's check the technical score of Armata Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5022.582
Ma 20Greater thanMa 501.738
Ma 50Greater thanMa 1001.917
Ma 100Greater thanMa 2002.034
OpenGreater thanClose1.290
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Armata Pharmaceuticals Inc

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.

Fundamental data was last updated by Penke on 2025-03-28 09:41:06.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is cheap.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Armata Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Armata Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Armata Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-647.5%+647.5%
TTM-647.5%YOY-1,605.0%+957.4%
TTM-647.5%5Y-36,200.3%+35,552.7%
5Y-36,200.3%10Y-20,820.8%-15,379.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--109.6%+109.6%
TTM-647.5%-185.9%-461.6%
YOY-1,605.0%-206.2%-1,398.8%
5Y-36,200.3%-408.8%-35,791.5%
10Y-20,820.8%-522.9%-20,297.9%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Armata Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Armata Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • 3.0% Return on Assets means thatΒ Armata Pharmaceuticals Inc generatedΒ $0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Armata Pharmaceuticals Inc:

  • The MRQ is 3.0%. Using its assets, the company is less efficient in making profit.
  • The TTM is -3.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ3.0%TTM-3.8%+6.8%
TTM-3.8%YOY-16.3%+12.6%
TTM-3.8%5Y-10.6%+6.9%
5Y-10.6%10Y-13.5%+2.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.0%-14.2%+17.2%
TTM-3.8%-14.6%+10.8%
YOY-16.3%-14.4%-1.9%
5Y-10.6%-15.5%+4.9%
10Y-13.5%-18.0%+4.5%
4.3.1.3. Return on Equity

Shows how efficient Armata Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Armata Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • 0.0% Return on Equity means Armata Pharmaceuticals Inc generated $0.00Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Armata Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-24.3%+24.3%
TTM-5Y-17.5%+17.5%
5Y-17.5%10Y-21.4%+3.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--17.6%+17.6%
TTM--18.2%+18.2%
YOY-24.3%-19.1%-5.2%
5Y-17.5%-24.3%+6.8%
10Y-21.4%-26.0%+4.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Armata Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Armata Pharmaceuticals Inc is operatingΒ .

  • Measures how much profit Armata Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Armata Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Armata Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-600.4%+600.4%
TTM-600.4%YOY-1,595.9%+995.4%
TTM-600.4%5Y-39,086.8%+38,486.4%
5Y-39,086.8%10Y-21,349.6%-17,737.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--223.7%+223.7%
TTM-600.4%-281.1%-319.3%
YOY-1,595.9%-226.6%-1,369.3%
5Y-39,086.8%-393.8%-38,693.0%
10Y-21,349.6%-503.6%-20,846.0%
4.3.2.2. Operating Ratio

Measures how efficient Armata Pharmaceuticals Inc is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Armata Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM2.897-2.897
TTM2.897YOY10.115-7.218
TTM2.8975Y389.242-386.345
5Y389.24210Y218.411+170.830
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.324-2.324
TTM2.8973.192-0.295
YOY10.1153.069+7.046
5Y389.2425.133+384.109
10Y218.4117.010+211.401
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Armata Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Armata Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 0.23Β means the company has $0.23 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Armata Pharmaceuticals Inc:

  • The MRQ is 0.234. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.263. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.234TTM0.263-0.029
TTM0.263YOY1.027-0.763
TTM0.2635Y2.522-2.259
5Y2.52210Y2.726-0.204
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2343.776-3.542
TTM0.2633.930-3.667
YOY1.0274.470-3.443
5Y2.5225.748-3.226
10Y2.7266.099-3.373
4.4.3.2. Quick Ratio

Measures if Armata Pharmaceuticals Inc is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Armata Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • A Quick Ratio of 0.21Β means the company can pay off $0.21 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Armata Pharmaceuticals Inc:

  • The MRQ is 0.208. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.239. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.208TTM0.239-0.031
TTM0.239YOY0.858-0.619
TTM0.2395Y2.332-2.093
5Y2.33210Y2.545-0.213
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2083.102-2.894
TTM0.2393.367-3.128
YOY0.8584.358-3.500
5Y2.3325.731-3.399
10Y2.5456.427-3.882
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Armata Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Armata Pharmaceuticals IncΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Armata Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.56Β means that Armata Pharmaceuticals Inc assets areΒ financed with 155.6% credit (debt) and the remaining percentage (100% - 155.6%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Armata Pharmaceuticals Inc:

  • The MRQ is 1.556. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.492. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ1.556TTM1.492+0.063
TTM1.492YOY1.001+0.491
TTM1.4925Y0.774+0.718
5Y0.77410Y0.603+0.171
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5560.340+1.216
TTM1.4920.340+1.152
YOY1.0010.318+0.683
5Y0.7740.364+0.410
10Y0.6030.393+0.210
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Armata Pharmaceuticals Inc is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Armata Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Armata Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY2.033-2.033
TTM-5Y0.960-0.960
5Y0.96010Y1.045-0.085
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.399-0.399
TTM-0.407-0.407
YOY2.0330.389+1.644
5Y0.9600.428+0.532
10Y1.0450.460+0.585
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Armata Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced butΒ always compareΒ Armata Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • A PE ratio of 10.51 means the investor is paying $10.51Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Armata Pharmaceuticals Inc:

  • The EOD is 7.272. Based on the earnings, the company is cheap. +2
  • The MRQ is 10.510. Based on the earnings, the company is underpriced. +1
  • The TTM is 2.386. Based on the earnings, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD7.272MRQ10.510-3.238
MRQ10.510TTM2.386+8.124
TTM2.386YOY-1.574+3.960
TTM2.3865Y-3.058+5.444
5Y-3.05810Y-3.234+0.176
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD7.272-1.736+9.008
MRQ10.510-2.674+13.184
TTM2.386-3.229+5.615
YOY-1.574-3.337+1.763
5Y-3.058-6.386+3.328
10Y-3.234-7.280+4.046
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Armata Pharmaceuticals Inc:

  • The EOD is -2.408. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.481. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.192. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.408MRQ-3.481+1.073
MRQ-3.481TTM-3.192-0.289
TTM-3.192YOY-1.614-1.578
TTM-3.1925Y-4.610+1.417
5Y-4.61010Y-5.167+0.557
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.408-2.257-0.151
MRQ-3.481-3.660+0.179
TTM-3.192-4.254+1.062
YOY-1.614-4.479+2.865
5Y-4.610-8.682+4.072
10Y-5.167-9.845+4.678
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Armata Pharmaceuticals Inc is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of -2.28 means the investor is paying $-2.28Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Armata Pharmaceuticals Inc:

  • The EOD is -1.575. Based on the equity, the company is expensive. -2
  • The MRQ is -2.276. Based on the equity, the company is expensive. -2
  • The TTM is -2.527. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.575MRQ-2.276+0.701
MRQ-2.276TTM-2.527+0.251
TTM-2.527YOY-1.893-0.634
TTM-2.5275Y1.720-4.247
5Y1.72010Y3.345-1.625
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.5751.641-3.216
MRQ-2.2762.266-4.542
TTM-2.5272.443-4.970
YOY-1.8932.468-4.361
5Y1.7203.790-2.070
10Y3.3454.287-0.942
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Armata Pharmaceuticals Inc.

3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets86,437
Total Liabilities134,456
Total Stockholder Equity-48,019
 As reported
Total Liabilities 134,456
Total Stockholder Equity+ -48,019
Total Assets = 86,437

Assets

Total Assets86,437
Total Current Assets11,308
Long-term Assets75,129
Total Current Assets
Cash And Cash Equivalents 9,291
Net Receivables 744
Other Current Assets 1,273
Total Current Assets  (as reported)11,308
Total Current Assets  (calculated)11,308
+/-0
Long-term Assets
Property Plant Equipment 54,928
Goodwill 3,490
Intangible Assets 13,746
Long-term Assets  (as reported)75,129
Long-term Assets  (calculated)72,164
+/- 2,965

Liabilities & Shareholders' Equity

Total Current Liabilities48,249
Long-term Liabilities86,207
Total Stockholder Equity-48,019
Total Current Liabilities
Short-term Debt 38,954
Short Long Term Debt 38,954
Accounts payable 766
Other Current Liabilities 8,529
Total Current Liabilities  (as reported)48,249
Total Current Liabilities  (calculated)87,203
+/- 38,954
Long-term Liabilities
Long term Debt 55,436
Capital Lease Obligations 32,125
Long-term Liabilities  (as reported)86,207
Long-term Liabilities  (calculated)87,561
+/- 1,354
Total Stockholder Equity
Retained Earnings -327,735
Other Stockholders Equity 279,716
Total Stockholder Equity (as reported)-48,019
Total Stockholder Equity (calculated)-48,019
+/-0
Other
Capital Stock362
Cash and Short Term Investments 9,291
Common Stock Shares Outstanding 59,082
Liabilities and Stockholders Equity 86,437
Net Debt 57,357
Net Invested Capital 46,371
Net Working Capital -36,941
Property Plant and Equipment Gross 68,074
Short Long Term Debt Total 66,648



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312011-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-311999-12-311999-09-301999-06-301999-03-311998-12-311998-09-301998-06-301998-03-311997-12-311997-09-301997-06-301997-03-311996-12-311996-09-301996-06-301996-03-311995-12-311995-09-301995-06-301995-03-311994-12-311994-09-301994-06-301994-03-311993-12-311993-09-301993-06-301993-03-31
> Total Assets 
0
0
0
12,100
0
21,000
18,600
17,000
14,400
11,900
21,700
20,000
17,400
30,500
27,800
25,100
21,200
17,300
14,200
9,800
6,700
15,800
12,200
16,200
13,200
11,000
14,200
13,700
38,889
35,348
84,780
87,974
83,311
75,100
73,322
71,038
62,096
62,595
59,651
52,712
50,623
62,314
63,013
57,672
77,116
73,273
67,383
69,965
65,410
60,370
52,423
48,798
51,083
22,985
19,945
17,467
21,618
37,473
31,508
28,474
24,248
22,713
19,184
7,150
5,471
4,077
4,530
11,480
22,070
0
0
22,740
37,947
37,947
31,262
28,419
28,617
28,617
36,372
34,078
31,493
28,261
29,279
26,036
18,195
14,302
15,106
13,781
11,138
14,399
11,720
10,619
11,887
9,617
34,916
29,304
25,451
44,102
49,461
45,675
39,516
52,845
48,281
42,671
69,768
107,765
100,984
92,881
95,834
108,779
101,212
112,761
109,964
120,356
108,313
98,237
86,437
86,43798,237108,313120,356109,964112,761101,212108,77995,83492,881100,984107,76569,76842,67148,28152,84539,51645,67549,46144,10225,45129,30434,9169,61711,88710,61911,72014,39911,13813,78115,10614,30218,19526,03629,27928,26131,49334,07836,37228,61728,61728,41931,26237,94737,94722,7400022,07011,4804,5304,0775,4717,15019,18422,71324,24828,47431,50837,47321,61817,46719,94522,98551,08348,79852,42360,37065,41069,96567,38373,27377,11657,67263,01362,31450,62352,71259,65162,59562,09671,03873,32275,10083,31187,97484,78035,34838,88913,70014,20011,00013,20016,20012,20015,8006,7009,80014,20017,30021,20025,10027,80030,50017,40020,00021,70011,90014,40017,00018,60021,000012,100000
   > Total Current Assets 
0
0
0
6,900
0
15,700
13,300
11,700
9,100
6,700
16,300
14,600
12,000
25,000
22,200
19,500
15,800
12,200
9,500
5,300
2,100
11,500
8,200
12,400
9,200
6,800
10,000
9,300
34,588
31,361
39,828
42,185
38,207
30,165
29,861
29,489
21,310
22,597
20,347
14,228
12,923
25,332
26,591
21,632
41,482
37,935
32,115
35,153
30,802
26,370
18,461
15,185
17,608
13,407
10,528
8,235
12,538
28,294
22,396
19,296
15,193
13,283
9,766
5,665
4,294
2,992
4,234
1,620
1,650
0
0
5,310
20,534
20,534
12,983
10,092
7,020
7,020
14,863
12,562
10,016
6,753
7,738
4,561
6,355
2,560
9,244
7,989
5,385
8,743
6,120
5,114
8,408
5,942
14,202
9,934
6,655
25,776
20,684
17,024
10,846
24,039
19,709
14,178
14,995
48,699
41,306
33,245
27,047
38,595
26,834
36,585
19,151
41,717
30,903
22,389
11,308
11,30822,38930,90341,71719,15136,58526,83438,59527,04733,24541,30648,69914,99514,17819,70924,03910,84617,02420,68425,7766,6559,93414,2025,9428,4085,1146,1208,7435,3857,9899,2442,5606,3554,5617,7386,75310,01612,56214,8637,0207,02010,09212,98320,53420,5345,310001,6501,6204,2342,9924,2945,6659,76613,28315,19319,29622,39628,29412,5388,23510,52813,40717,60815,18518,46126,37030,80235,15332,11537,93541,48221,63226,59125,33212,92314,22820,34722,59721,31029,48929,86130,16538,20742,18539,82831,36134,5889,30010,0006,8009,20012,4008,20011,5002,1005,3009,50012,20015,80019,50022,20025,00012,00014,60016,3006,7009,10011,70013,30015,70006,900000
       Cash And Cash Equivalents 
0
0
0
1,200
0
6,100
3,600
2,300
500
300
3,000
2,200
1,500
7,200
2,200
3,500
900
200
3,200
1,000
600
1,700
1,700
1,900
600
2,000
5,000
4,100
29,336
27,941
38,831
38,630
34,034
26,582
28,187
25,186
17,023
17,273
17,269
12,606
12,231
24,752
26,118
21,057
41,119
37,381
31,333
34,096
30,423
25,609
17,151
14,122
15,998
12,171
9,280
6,206
11,254
26,045
20,531
16,442
12,862
12,701
9,183
5,216
3,916
2,469
3,974
1,100
860
0
0
4,860
20,355
20,355
12,550
9,786
6,581
6,581
14,351
11,737
9,370
6,173
7,144
3,967
5,711
2,202
8,962
7,725
5,132
8,206
5,798
4,499
8,157
5,535
13,192
8,690
6,033
24,209
19,786
15,885
9,649
22,455
17,536
12,076
10,288
46,408
36,978
25,382
14,852
25,106
12,456
23,958
13,523
37,860
26,405
17,141
9,291
9,29117,14126,40537,86013,52323,95812,45625,10614,85225,38236,97846,40810,28812,07617,53622,4559,64915,88519,78624,2096,0338,69013,1925,5358,1574,4995,7988,2065,1327,7258,9622,2025,7113,9677,1446,1739,37011,73714,3516,5816,5819,78612,55020,35520,3554,860008601,1003,9742,4693,9165,2169,18312,70112,86216,44220,53126,04511,2546,2069,28012,17115,99814,12217,15125,60930,42334,09631,33337,38141,11921,05726,11824,75212,23112,60617,26917,27317,02325,18628,18726,58234,03438,63038,83127,94129,3364,1005,0002,0006001,9001,7001,7006001,0003,2002009003,5002,2007,2001,5002,2003,0003005002,3003,6006,10001,200000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,600
3,100
3,046
1,532
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000000000000000000000000000000000000000000000001,5323,0463,1003,60000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
300
1,000
1,300
1,800
1,975
1,355
639
3,264
3,643
2,553
954
3,368
3,368
4,259
2,238
1,170
1,170
7
25
166
8
0
1
404
104
124
611
380
991
290
613
1,498
944
1,874
1,544
2,611
2,060
255
368
317
257
129
7
120
20
0
0
10
8
8
136
27
100
100
0
40
125
14
18
24
644
15
0
0
0
0
0
0
0
0
0
0
0
1,000
0
335
561
1,125
1,168
1,251
2,989
1,236
1,883
1,867
1,936
1,257
8,633
8,497
3,363
1,714
1,242
2,219
744
7442,2191,2421,7143,3638,4978,6331,2571,9361,8671,8831,2362,9891,2511,1681,12556133501,0000000000000015644241814125400100100271368810002012071292573173682552,0602,6111,5441,8749441,4986132909913806111241044041081662571,1701,1702,2384,2593,3683,3689542,5533,6433,2646391,3551,9751,8001,3001,000300000000000000000000000000
       Other Current Assets 
0
0
0
5,700
0
9,600
9,700
9,400
8,600
6,400
13,300
12,400
10,500
17,800
20,000
16,000
14,900
12,000
6,300
4,300
1,500
9,800
6,500
10,500
8,300
3,800
100
300
231
533
358
291
530
1,030
720
935
919
1,065
840
452
692
573
448
409
355
554
781
653
275
637
699
683
619
946
635
531
340
375
321
243
271
327
215
132
121
394
253
400
770
0
0
440
0
171
297
279
0
339
512
785
521
566
576
570
619
343
282
264
253
537
322
615
251
407
1,010
1,244
622
567
898
804
636
459
1,005
851
1,718
1,055
2,445
5,996
10,259
12,232
5,745
4,130
2,265
2,143
3,256
3,029
1,273
1,2733,0293,2562,1432,2654,1305,74512,23210,2595,9962,4451,0551,7188511,0054596368048985676221,2441,01040725161532253725326428234361957057656652178551233902792971710440007704002533941211322153272712433213753405316359466196836996372756537815543554094485736924528401,0659199357201,0305302913585332313001003,8008,30010,5006,5009,8001,5004,3006,30012,00014,90016,00020,00017,80010,50012,40013,3006,4008,6009,4009,7009,60005,700000
   > Long-term Assets 
0
0
0
5,200
0
5,300
5,300
5,300
5,300
5,200
5,400
5,400
5,400
5,500
5,600
5,600
5,400
5,100
4,700
4,500
4,600
4,300
4,000
3,800
4,000
4,200
4,200
4,400
4,301
3,987
44,952
45,789
45,104
44,935
43,461
41,549
40,786
39,998
39,304
38,484
37,700
36,982
36,422
36,040
35,634
35,338
35,268
34,812
34,608
34,000
33,962
33,613
33,475
9,578
9,417
9,232
9,080
9,179
9,112
9,178
9,055
9,430
9,418
1,485
1,177
1,085
296
9,860
20,420
0
0
17,430
0
17,413
18,279
18,327
0
21,597
21,509
21,516
21,477
21,508
21,541
21,475
11,840
11,742
5,862
5,792
5,753
5,656
5,600
5,505
3,479
3,675
20,714
19,370
18,797
18,326
28,777
28,651
28,670
28,806
28,572
28,493
54,773
59,066
59,678
59,636
68,787
70,184
74,378
76,176
90,813
78,639
77,410
75,848
75,129
75,12975,84877,41078,63990,81376,17674,37870,18468,78759,63659,67859,06654,77328,49328,57228,80628,67028,65128,77718,32618,79719,37020,7143,6753,4795,5055,6005,6565,7535,7925,86211,74211,84021,47521,54121,50821,47721,51621,50921,597018,32718,27917,413017,4300020,4209,8602961,0851,1771,4859,4189,4309,0559,1789,1129,1799,0809,2329,4179,57833,47533,61333,96234,00034,60834,81235,26835,33835,63436,04036,42236,98237,70038,48439,30439,99840,78641,54943,46144,93545,10445,78944,9523,9874,3014,4004,2004,2004,0003,8004,0004,3004,6004,5004,7005,1005,4005,6005,6005,5005,4005,4005,4005,2005,3005,3005,3005,30005,200000
       Property Plant Equipment 
0
0
0
4,900
0
4,800
4,900
5,000
4,900
4,900
5,100
5,000
5,000
5,100
5,000
5,000
4,900
4,500
4,200
3,900
4,100
3,800
3,500
3,300
3,500
3,800
3,700
4,000
3,921
3,613
4,505
6,206
7,321
8,635
8,589
8,308
7,698
7,087
6,407
5,520
4,779
4,093
3,583
3,423
3,159
2,876
2,756
2,495
2,351
2,150
2,104
1,747
1,611
1,440
1,282
1,100
951
1,053
986
1,052
929
1,304
1,292
1,285
1,177
1,085
296
140
140
0
0
170
145
145
1,119
1,175
1,220
1,220
1,147
1,162
1,131
1,170
1,210
1,152
1,072
982
909
847
816
727
678
591
503
706
6,132
4,788
4,215
3,844
12,952
12,819
12,837
12,811
12,739
12,638
38,072
37,665
38,277
38,977
46,652
48,265
52,459
54,136
57,276
56,943
57,145
55,867
54,928
54,92855,86757,14556,94357,27654,13652,45948,26546,65238,97738,27737,66538,07212,63812,73912,81112,83712,81912,9523,8444,2154,7886,1327065035916787278168479099821,0721,1521,2101,1701,1311,1621,1471,2201,2201,1751,119145145170001401402961,0851,1771,2851,2921,3049291,0529861,0539511,1001,2821,4401,6111,7472,1042,1502,3512,4952,7562,8763,1593,4233,5834,0934,7795,5206,4077,0877,6988,3088,5898,6357,3216,2064,5053,6133,9214,0003,7003,8003,5003,3003,5003,8004,1003,9004,2004,5004,9005,0005,0005,1005,0005,0005,1004,9004,9005,0004,9004,80004,900000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
31,649,000,000
31,649
31,649,000,000
0
31,649
31,649
31,649
31,649
31,649
31,649
31,649
31,649
31,649
31,649
7,926
7,926
7,926
7,926
7,926
7,926
7,926
7,926
7,926
7,926
0
0
0
0
9,730
7,410
0
0
4,330
4,329
4,329
4,329
4,329
7,562
7,562
7,562
7,562
7,562
7,562
7,562
7,562
0
0
0
0
0
0
0
0
0
0
3,490
3,490
3,490
3,490
3,490
3,490
3,490
3,490
3,490
3,490
3,490
3,490
3,490
3,490
3,490
3,490
3,490
3,490
3,490
3,490
3,490
3,490
3,490
3,4903,4903,4903,4903,4903,4903,4903,4903,4903,4903,4903,4903,4903,4903,4903,4903,4903,4903,4903,4903,4903,4903,49000000000007,5627,5627,5627,5627,5627,5627,5627,5624,3294,3294,3294,3294,330007,4109,73000007,9267,9267,9267,9267,9267,9267,9267,9267,9267,92631,64931,64931,64931,64931,64931,64931,64931,64931,64931,649031,649,000,00031,64931,649,000,000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
300
0
400
300
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
39,488
37,821
36,304
34,786
33,269
31,752
31,625
31,499
31,520
31,649
31,649
31,649
31,649
31,649
31,649
31,649
31,649
31,649
31,649
31,649
31,649
31,649
31,649
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,880
0
0
12,940
12,939
12,939
12,831
12,823
12,815
12,815
12,800
12,792
12,784
12,776
12,769
12,761
10,768
10,760
4,953
4,945
4,937
4,929
4,922
4,914
2,976
2,969
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
13,746
13,74610,25610,25610,25610,25610,25610,25610,25610,25610,25610,25610,25610,25610,25610,25610,25610,25610,25610,25610,25610,25610,25610,2562,9692,9764,9144,9224,9294,9374,9454,95310,76010,76812,76112,76912,77612,78412,79212,80012,81512,81512,82312,83112,93912,93912,9400012,88000000000000000031,64931,64931,64931,64931,64931,64931,64931,64931,64931,64931,64931,64931,64931,64931,52031,49931,62531,75233,26934,78636,30437,82139,488000000000000000000000003004000300000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
836
11,092
11,092
-1
10,992
12,335
23,211
23,133
12,505
12,343
2,109
13,211
17,911
17,911
17,169
18,645
0
8,173
0
0
0
0
0
0
0000008,173018,64517,16917,91117,91113,2112,10912,34312,50523,13323,21112,33510,992-111,09211,092836000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
> Total Liabilities 
0
0
0
1,900
0
3,200
3,100
3,800
3,700
3,500
3,300
4,200
4,300
6,200
5,100
5,600
4,900
4,800
4,500
4,200
4,900
4,400
4,100
4,200
3,900
4,400
4,300
6,700
6,299
6,745
12,418
24,542
23,823
20,929
28,110
33,637
31,065
50,016
47,773
46,066
44,807
35,232
22,495
23,443
23,932
24,559
21,381
20,203
20,314
20,568
18,248
18,227
19,175
18,603
18,461
12,100
11,777
13,696
10,640
12,234
11,227
13,248
12,243
10,922
10,875
2,099
1,797
4,330
9,130
0
0
52,240
52,168
52,168
40,283
17,081
25,180
25,180
23,284
18,415
18,779
19,364
7,795
7,808
8,472
7,654
5,245
4,024
3,407
3,109
3,381
3,766
3,413
4,656
12,286
11,172
10,858
10,620
19,823
21,056
20,659
18,833
19,662
18,916
44,371
46,226
47,693
47,304
59,754
86,332
82,069
125,147
142,029
176,866
154,414
149,210
134,456
134,456149,210154,414176,866142,029125,14782,06986,33259,75447,30447,69346,22644,37118,91619,66218,83320,65921,05619,82310,62010,85811,17212,2864,6563,4133,7663,3813,1093,4074,0245,2457,6548,4727,8087,79519,36418,77918,41523,28425,18025,18017,08140,28352,16852,16852,240009,1304,3301,7972,09910,87510,92212,24313,24811,22712,23410,64013,69611,77712,10018,46118,60319,17518,22718,24820,56820,31420,20321,38124,55923,93223,44322,49535,23244,80746,06647,77350,01631,06533,63728,11020,92923,82324,54212,4186,7456,2996,7004,3004,4003,9004,2004,1004,4004,9004,2004,5004,8004,9005,6005,1006,2004,3004,2003,3003,5003,7003,8003,1003,20001,900000
   > Total Current Liabilities 
0
0
0
900
0
1,400
1,300
1,600
1,300
1,300
1,300
1,800
1,600
3,800
2,900
3,500
3,000
2,800
2,700
2,700
3,200
2,900
2,800
3,300
2,900
3,200
3,200
4,600
4,153
4,425
7,153
12,686
14,183
10,865
10,359
11,628
9,804
12,377
12,436
11,282
10,197
11,142
7,471
6,709
7,475
8,328
4,848
3,995
4,041
4,576
3,685
4,628
3,917
4,001
6,568
5,188
5,812
6,598
5,125
4,657
3,804
5,983
5,140
3,986
4,109
2,008
1,797
1,510
6,050
0
0
1,480
2,147
2,147
1,366
2,499
1,868
1,868
2,167
2,259
2,385
2,651
3,324
3,154
3,580
2,876
3,711
2,477
1,968
1,775
2,049
2,465
2,572
3,591
5,634
4,965
4,879
6,357
5,207
7,070
6,705
4,981
5,903
5,254
4,814
6,226
7,383
7,004
24,873
51,415
51,562
21,884
16,461
110,045
123,181
118,204
48,249
48,249118,204123,181110,04516,46121,88451,56251,41524,8737,0047,3836,2264,8145,2545,9034,9816,7057,0705,2076,3574,8794,9655,6343,5912,5722,4652,0491,7751,9682,4773,7112,8763,5803,1543,3242,6512,3852,2592,1671,8681,8682,4991,3662,1472,1471,480006,0501,5101,7972,0084,1093,9865,1405,9833,8044,6575,1256,5985,8125,1886,5684,0013,9174,6283,6854,5764,0413,9954,8488,3287,4756,7097,47111,14210,19711,28212,43612,3779,80411,62810,35910,86514,18312,6867,1534,4254,1534,6003,2003,2002,9003,3002,8002,9003,2002,7002,7002,8003,0003,5002,9003,8001,6001,8001,3001,3001,3001,6001,3001,4000900000
       Short-term Debt 
0
0
0
200
0
400
400
600
600
600
700
900
1,000
1,100
1,100
1,300
1,300
1,100
1,000
1,000
1,200
1,200
1,100
1,200
1,300
1,400
1,200
1,200
1,100
1,041
986
838
813
970
1,652
1,308
1,197
1,253
1,214
1,298
1,624
1,567
1,332
1,290
1,280
1,511
1,344
1,269
982
873
188
155
116
65
3,195
1,129
1,114
1,224
504
336
335
335
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,547
0
0
0
0
0
0
803
598
606
305
0
0
0
0
0
1,143
1,264
1,251
1,308
1,366
1,123
2,126
2,273
2,332
2,392
1,729
1,509
1,520
1,706
2,223
17,011
45,492
26,352
13,443
18,962
104,165
124,580
112,397
38,954
38,954112,397124,580104,16518,96213,44326,35245,49217,0112,2231,7061,5201,5091,7292,3922,3322,2732,1261,1231,3661,3081,2511,2641,143000003056065988030000001,5470000000000000003353353365041,2241,1141,1293,195651161551888739821,2691,3441,5111,2801,2901,3321,5671,6241,2981,2141,2531,1971,3081,6529708138389861,0411,1001,2001,2001,4001,3001,2001,1001,2001,2001,0001,0001,1001,3001,3001,1001,1001,0009007006006006004004000200000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,143
0
0
0
0
718
720
722
724
725
0
0
0
0
0
0
32,388
26,352
0
0
96,668
111,388
107,403
38,954
38,954107,403111,38896,6680026,35232,38800000072572472272071800001,143000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
0
0
0
600
0
800
700
700
500
500
400
600
400
2,500
1,600
1,900
1,400
1,300
1,400
1,400
1,800
1,500
1,400
1,700
1,400
1,600
1,700
2,300
1,851
2,275
4,267
4,000
3,878
1,766
2,049
3,452
3,165
3,130
2,941
2,012
1,936
1,875
1,301
1,271
1,464
1,988
1,833
1,289
2,217
2,464
1,880
1,770
1,840
2,173
1,895
1,901
2,213
4,005
2,058
2,161
2,307
2,844
2,144
0
0
0
0
0
0
0
0
0
0
2,147
0
0
0
1,547
1,365
1,153
1,464
2,003
2,239
2,173
1,659
1,109
1,856
949
578
810
682
714
729
154
1,768
1,261
547
1,447
1,501
1,871
956
5,726
2,296
1,811
1,138
7,783
4,021
2,977
1,678
5,000
9,584
3,772
1,585
2,057
1,743
1,815
766
7661,8151,7432,0571,5853,7729,5845,0001,6782,9774,0217,7831,1381,8112,2965,7269561,8711,5011,4475471,2611,7681547297146828105789491,8561,1091,6592,1732,2392,0031,4641,1531,3651,5470002,14700000000002,1442,8442,3072,1612,0584,0052,2131,9011,8952,1731,8401,7701,8802,4642,2171,2891,8331,9881,4641,2711,3011,8751,9362,0122,9413,1303,1653,4522,0491,7663,8784,0004,2672,2751,8512,3001,7001,6001,4001,7001,4001,5001,8001,4001,4001,3001,4001,9001,6002,5004006004005005007007008000600000
       Other Current Liabilities 
0
0
0
100
0
200
200
300
200
200
200
300
200
200
200
300
300
400
300
300
200
200
300
400
200
200
300
1,100
1,201
1,108
1,900
7,848
1,914
1,376
1,540
2,237
969
1,922
1,356
1,931
1,313
2,463
2,473
2,968
1,947
2,062
1,167
1,437
842
1,096
1,617
2,425
1,211
1,620
1,155
1,907
2,392
1,302
2,345
2,081
1,078
1,131
1,131
2,759
2,333
1,706
1,315
1,510
6,050
0
0
1,480
0
-139,121
-347,634
-243,501
0
1,624
452
859
676
506
1,042
963
185
1,083
1,191
1,203
1,390
965
1,367
1,751
1,843
3,591
4,370
3,714
3,024
4,991
4,084
4,944
3,476
2,649
3,511
3,525
2,167
4,706
5,677
4,781
6,184
5,923
25,210
4,669
-4,086
3,823
-3,142
3,992
8,529
8,5293,992-3,1423,823-4,0864,66925,2105,9236,1844,7815,6774,7062,1673,5253,5112,6493,4764,9444,0844,9913,0243,7144,3703,5911,8431,7511,3679651,3901,2031,1911,0831859631,0425066768594521,6240-243,501-347,634-139,12101,480006,0501,5101,3151,7062,3332,7591,1311,1311,0782,0812,3451,3022,3921,9071,1551,6201,2112,4251,6171,0968421,4371,1672,0621,9472,9682,4732,4631,3131,9311,3561,9229692,2371,5401,3761,9147,8481,9001,1081,2011,1003002002004003002002003003004003003002002002003002002002003002002000100000
   > Long-term Liabilities 
0
0
0
1,000
0
1,800
1,800
2,200
2,400
2,200
2,000
2,400
2,700
2,400
2,200
2,100
1,900
2,000
1,800
1,500
1,700
1,500
1,300
900
1,000
1,200
1,100
2,100
2,147
2,321
5,265
11,856
9,640
10,064
17,751
22,009
21,261
37,639
35,337
34,784
34,610
24,090
15,024
16,734
16,457
16,231
16,533
16,208
16,273
15,992
14,563
13,599
15,258
14,602
11,893
6,912
5,965
7,098
5,515
7,577
7,423
7,265
7,103
6,936
6,766
91
482
2,820
3,080
0
0
50,760
0
50,021
38,917
14,582
0
23,312
21,117
16,156
16,394
16,713
4,471
4,654
4,892
4,778
1,534
1,547
1,439
1,334
1,332
1,301
841
1,065
6,652
6,207
5,979
4,263
14,616
13,986
13,954
13,852
13,759
13,662
39,557
40,000
40,310
40,300
34,881
34,917
30,507
103,263
125,568
66,821
31,233
31,006
86,207
86,20731,00631,23366,821125,568103,26330,50734,91734,88140,30040,31040,00039,55713,66213,75913,85213,95413,98614,6164,2635,9796,2076,6521,0658411,3011,3321,3341,4391,5471,5344,7784,8924,6544,47116,71316,39416,15621,11723,312014,58238,91750,021050,760003,0802,820482916,7666,9367,1037,2657,4237,5775,5157,0985,9656,91211,89314,60215,25813,59914,56315,99216,27316,20816,53316,23116,45716,73415,02424,09034,61034,78435,33737,63921,26122,00917,75110,0649,64011,8565,2652,3212,1472,1001,1001,2001,0009001,3001,5001,7001,5001,8002,0001,9002,1002,2002,4002,7002,4002,0002,2002,4002,2001,8001,80001,000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,556
4,239
4,307
4,424
3,077
3,077
3,077
3,077
3,077
3,077
13,662
3,077
3,077
3,077
3,077
3,077
0
30,507
0
0
0
0
0
0
00000030,50703,0773,0773,0773,0773,07713,6623,0773,0773,0773,0773,0773,0774,4244,3074,2393,556000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
10,256
0
0
0
0
0
0
0
0
0000000010,25610,25610,25610,25610,25610,25610,25610,25610,25610,25610,25610,25610,25610,25610,2560000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
10,200
0
17,800
15,500
13,200
10,700
8,400
18,400
15,800
13,100
24,300
22,700
19,500
16,300
12,500
9,700
5,600
1,800
11,400
8,100
12,000
9,300
6,600
9,900
7,000
32,589
28,602
72,362
63,432
59,487
54,172
45,213
37,401
31,031
12,579
11,878
5,896
5,066
26,332
39,768
33,479
53,184
48,714
46,002
49,762
45,096
39,802
34,175
30,571
31,908
4,382
1,484
5,367
9,841
23,777
20,868
16,240
13,021
9,465
6,941
-3,772
-5,404
1,978
2,733
7,150
12,940
0
0
-29,500
0
-14,221
-9,021
11,338
0
3,437
13,088
15,663
12,714
8,897
21,484
18,228
9,723
6,648
9,861
9,757
7,731
11,290
8,339
6,853
8,474
4,961
22,630
18,132
14,593
33,482
29,638
24,619
18,857
34,012
28,619
23,755
25,397
61,539
53,291
45,577
36,080
22,447
19,143
-12,386
-32,065
-56,510
-46,101
-50,973
-48,019
-48,019-50,973-46,101-56,510-32,065-12,38619,14322,44736,08045,57753,29161,53925,39723,75528,61934,01218,85724,61929,63833,48214,59318,13222,6304,9618,4746,8538,33911,2907,7319,7579,8616,6489,72318,22821,4848,89712,71415,66313,0883,437011,338-9,021-14,2210-29,5000012,9407,1502,7331,978-5,404-3,7726,9419,46513,02116,24020,86823,7779,8415,3671,4844,38231,90830,57134,17539,80245,09649,76246,00248,71453,18433,47939,76826,3325,0665,89611,87812,57931,03137,40145,21354,17259,48763,43272,36228,60232,5897,0009,9006,6009,30012,0008,10011,4001,8005,6009,70012,50016,30019,50022,70024,30013,10015,80018,4008,40010,70013,20015,50017,800010,200000
   Common Stock
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
98,000
98,100
126,805
126,895
198,498
200,968
203,038
203,355
201,146
441
442
442
502
506
506
584
662
662
816
816
816
856
856
856
856
857
985
99
99
109
131
198
198
198
198
200
200
202
204
207
207
450
670
0
0
1,020
0
1,825
1,872
1,872
0
1,992
57
59
59
59
111
111
165
165
85
93
95
165
165
165
323
328
99
99
99
186
186
187
187
249
249
249
271
361
361
361
361
361
361
361
361
361
362
362
0
0362362361361361361361361361361361271249249249187187186186999999328323165165165959385165165111111595959571,99201,8721,8721,82501,020006704502072072042022002001981981981981311099999985857856856856856816816816662662584506506502442442441201,146203,355203,038200,968198,498126,895126,80598,10098,00000000000000000000000000000
   Retained Earnings Total Equity000000-257,811-254,264-239,774-229,460-220,846-211,631-202,857-196,810-191,391-185,197-179,7020000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
-400
0
-400
-400
-1,400
-1,400
-1,400
-1,400
-2,900
-2,900
-2,900
-2,900
-4,700
-4,700
-5,400
-5,800
-6,200
-6,600
-7,000
-7,300
-6,200
-6,200
-6,200
-12,200
-12,300
-11
-3
-271
-13,276
-13,504
-13,737
-13,978
-12,015
-12,015
-12,015
-10,973
-11,062
-750,000,000
-12,015
-11,062
-13,482
-13,482
-13,482
-13,482
-13,654
-13,654
-13,654
55
-21
24
40
20
-39
-15,018
-15,018
6
-15,550
-15,550
-15,550
-15,550
-16,055
-16,055
0
-4,959
-180
-390
0
0
-160
-473
-65
-85
-178
-478
-19,425
-10,032
-2,127
-604
-91
-29,279
-26,036
-932
-14,302
-15,106
-13,781
-1,170
-1,170
0
0
-1,528
-1,528
-10,259
-9,090
-8,158
-8,454
-8,722
-8,780
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000-8,780-8,722-8,454-8,158-9,090-10,259-1,528-1,52800-1,170-1,170-13,781-15,106-14,302-932-26,036-29,279-91-604-2,127-10,032-19,425-478-178-85-65-473-16000-390-180-4,9590-16,055-16,055-15,550-15,550-15,550-15,5506-15,018-15,018-39204024-2155-13,654-13,654-13,654-13,482-13,482-13,482-13,482-11,062-12,015-750,000,000-11,062-10,973-12,015-12,015-12,015-13,978-13,737-13,504-13,276-271-3-11-12,300-12,200-6,200-6,200-6,200-7,300-7,000-6,600-6,200-5,800-5,400-4,700-4,700-2,900-2,900-2,900-2,900-1,400-1,400-1,400-1,400-400-4000-400000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
414,467
414,566
168,509
170,968
172,015
195,895
0
0
198,372
218,960
219,761
220,316
227,983
272,809
273,776
274,676
275,493
276,350
276,593
0
0
0
0
0
0
000000276,593276,350275,493274,676273,776272,809227,983220,316219,761218,960198,37200195,895172,015170,968168,509414,566414,46700000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
19,500
0
31,100
31,000
31,000
31,000
31,100
43,300
43,400
43,600
71,200
73,100
73,100
73,400
73,400
73,400
73,400
73,400
86,100
86,200
88,500
88,500
91,700
12,300
12,400
12,607
12,823
13,047
13,276
13,504
13,737
13,978
214,942
214,977
202,963
207,035
207,139
207,139
235,242
249,380
249,399
273,808
273,788
273,800
279,745
279,751
279,751
279,752
279,772
284,668
285,888
286,200
289,324
297,572
315,628
315,744
316,196
316,390
316,629
316,766
316,900
317,050
317,119
322,162
326,170
333,190
0
0
353,610
0
371,169
363,805
364,869
0
363,451
378,761
375,895
375,177
374,472
390,858
389,977
390,918
391,097
400,851
401,518
401,842
408,465
408,564
408,684
414,467
414,566
168,509
170,968
172,015
195,895
196,761
197,510
198,372
218,960
219,761
220,316
227,983
272,809
273,776
274,676
275,493
276,350
276,593
276,225
276,393
276,969
278,391
279,000
279,716
279,716279,000278,391276,969276,393276,225276,593276,350275,493274,676273,776272,809227,983220,316219,761218,960198,372197,510196,761195,895172,015170,968168,509414,566414,467408,684408,564408,465401,842401,518400,851391,097390,918389,977390,858374,472375,177375,895378,761363,4510364,869363,805371,1690353,61000333,190326,170322,162317,119317,050316,900316,766316,629316,390316,196315,744315,628297,572289,324286,200285,888284,668279,772279,752279,751279,751279,745273,800273,788273,808249,399249,380235,242207,139207,139207,035202,963214,977214,94213,97813,73713,50413,27613,04712,82312,60712,40012,30091,70088,50088,50086,20086,10073,40073,40073,40073,40073,40073,10073,10071,20043,60043,40043,30031,10031,00031,00031,00031,100019,500000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-47,610
Operating Income-42,436-47,610
 
Operating Expense (+$)
Research Development34,426
Selling General Administrative13,184
Selling And Marketing Expenses0
Operating Expense47,61047,610
 
Net Interest Income (+$)
Interest Income697
Interest Expense--10,742
Other Finance Cost-21,484
Net Interest Income-10,045
 
Pretax Income (+$)
Operating Income-42,436
Net Interest Income-10,045
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-18,916-65,956
EBIT - interestExpense = 10,742
-18,916
-29,658
Interest Expense-10,742
Earnings Before Interest and Taxes (EBIT)0-29,658
Earnings Before Interest and Taxes (EBITDA)-42,436
 
After tax Income (+$)
Income Before Tax-18,916
Tax Provision-0
Net Income From Continuing Ops-18,916-18,916
Net Income-18,916
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net23,52010,045
 

Technical Analysis of Armata Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Armata Pharmaceuticals Inc. The general trend of Armata Pharmaceuticals Inc is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Armata Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Armata Pharmaceuticals Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Armata Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.85 < 2.16 < 2.22.

The bearish price targets are: 1.24 > 1.1 > 1.1.

Know someone who trades $ARMP? Share this with them.πŸ‘‡

Armata Pharmaceuticals Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Armata Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Armata Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Armata Pharmaceuticals Inc. The current macd is -0.18021022.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Armata Pharmaceuticals Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Armata Pharmaceuticals Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Armata Pharmaceuticals Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Armata Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartArmata Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Armata Pharmaceuticals Inc. The current adx is 26.26.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Armata Pharmaceuticals Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Armata Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Armata Pharmaceuticals Inc. The current sar is 1.97173151.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Armata Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Armata Pharmaceuticals Inc. The current rsi is 22.58. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Armata Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartArmata Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Armata Pharmaceuticals Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Armata Pharmaceuticals Inc price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Armata Pharmaceuticals Inc Daily Stochastic Oscillator ChartArmata Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Armata Pharmaceuticals Inc. The current cci is -134.18421315.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Armata Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartArmata Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Armata Pharmaceuticals Inc. The current cmo is -66.48438339.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Armata Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartArmata Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Armata Pharmaceuticals Inc. The current willr is -88.69565217.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Armata Pharmaceuticals Inc Daily Williams %R ChartArmata Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Armata Pharmaceuticals Inc. The current atr is 0.15578338.

Armata Pharmaceuticals Inc Daily Average True Range (ATR) ChartArmata Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Armata Pharmaceuticals Inc. The current obv is 7,645,638.

Armata Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartArmata Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Armata Pharmaceuticals Inc. The current mfi is 6.48525885.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Armata Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartArmata Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Armata Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-11-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-12-03WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-16STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-18BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-23MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-12-24MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-12-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-12-31WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-07MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-01-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-22STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-01-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-01-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-07CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-18STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-19MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-02-25CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-03-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-03-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-24CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-26STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-27MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-28MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-31STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-03STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Armata Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Armata Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5022.582
Ma 20Greater thanMa 501.738
Ma 50Greater thanMa 1001.917
Ma 100Greater thanMa 2002.034
OpenGreater thanClose1.290
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Armata Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Armata Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Armata Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Armata Pharmaceuticals Inc

I send you an email if I find something interesting about Armata Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Armata Pharmaceuticals Inc.

Receive notifications about Armata Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.